Cargando…

SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer

SPARC/osteonectin expression is reportedly altered in various malignancies. However, little is known regarding to the prognostic value of SPARC in triple-negative breast cancer (TNBC) patients. In this study, immunohistochemistry and immunoreactive scores (IRSs) were used to evaluate SPARC protein e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Anjie, Yuan, Peng, Du, Feng, Hong, Ruoxi, Ding, Xiaoyan, Shi, Xiuqing, Fan, Ying, Wang, Jiayu, Luo, Yang, Ma, Fei, Zhang, Pin, Li, Qing, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363535/ https://www.ncbi.nlm.nih.gov/pubmed/27421134 http://dx.doi.org/10.18632/oncotarget.10532

Ejemplares similares

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer
por: Wang, Wenmiao, et al.
Publicado: (2016)

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice
por: Xiu, Meng, et al.
Publicado: (2022)

Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis
por: Zhang, Jingyi, et al.
Publicado: (2020)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer
por: Ma, Fei, et al.
Publicado: (2014)

Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries
por: Zhu, Wenjie, et al.
Publicado: (2015)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome
por: Wang, Peipei, et al.
Publicado: (2020)

Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer
por: Luo, Hanjia, et al.
Publicado: (2023)

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Overall survival of triple negative breast cancer in French Caribbean women
por: Beaubrun-Renard, Murielle Murielle, et al.
Publicado: (2022)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016)

LAG-3(+) tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients
por: Hu, Guoming, et al.
Publicado: (2023)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer
por: Shan, Zexing, et al.
Publicado: (2021)

Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia
por: Santoro, Marco, et al.
Publicado: (2022)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023)

SPARC Overexpression Promotes Liver Cancer Cell Proliferation and Tumor Growth
por: Gao, Zhao-wei, et al.
Publicado: (2021)

Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)
por: Ma, Fei, et al.
Publicado: (2017)

There Is No Association between MicroRNA Gene Polymorphisms and Risk of Triple Negative Breast Cancer in a Chinese Han Population
por: Ma, Fei, et al.
Publicado: (2013)

Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer
por: Oladeru, Oluwadamilola T., et al.
Publicado: (2020)

Nomogram for predicting overall survival in Chinese triple-negative breast cancer patients after surgery
por: Lin, Wei-Xun, et al.
Publicado: (2022)

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
por: Wang, Xue, et al.
Publicado: (2020)

Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance
por: Wang, C-S, et al.
Publicado: (2004)

SPARC overexpression alters microRNA expression profiles involved in tumor progression
por: Ahir, Bhavesh K., et al.
Publicado: (2017)

Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China
por: Tan, Yujing, et al.
Publicado: (2023)

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis
por: Han, Yiqun, et al.
Publicado: (2022)

SPARC's Initiative
por: Alison Buckholtz
Publicado: (2002)

Association between obesity with disease-free survival and overall survival in triple-negative breast cancer: A meta-analysis
por: Mei, Lin, et al.
Publicado: (2018)

Race is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review
por: Starlard-Davenport, Athena, et al.
Publicado: (2013)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial
por: Yuan, Peng, et al.
Publicado: (2023)

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vqkas4au1davptna05d43gtfl8